Daniela Becerra, BS | |
50680 Chiapas Dr, Coachella, CA 92236-5417 | |
(760) 989-2203 | |
Not Available |
Full Name | Daniela Becerra |
---|---|
Gender | Female |
Speciality | Psychologist - Cognitive & Behavioral |
Location | 50680 Chiapas Dr, Coachella, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1417660986 | NPI | - | NPPES |
XEIT50443772 | Other | CA | BLUE SHIELD OF CALIFORNIA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TB0200X | Psychologist - Cognitive & Behavioral | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Daniela Becerra, BS 50680 Chiapas Dr, Coachella, CA 92236-5417 Ph: (760) 989-2203 | Daniela Becerra, BS 50680 Chiapas Dr, Coachella, CA 92236-5417 Ph: (760) 989-2203 |
News Archive
The first new TB vaccine for more than 80 years has successfully come through safety trials in the UK. The vaccine, devised by a team led by Dr Helen McShane in Oxford's Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), is designed to be used in tandem with the tried and tested BCG inoculation – first introduced in 1921 – and not to replace it.
Experts at Virgen del Rocío Hospital (Seville, Spain) have begun a study on pregnancy preeclampsia on a sample of 30 pregnant women with a view to demonstrating whether or not consumption of olive oil by this population group results in lower levels of cytotoxicity (for example, cholesterol) in endothelial cells (arterial wall cells).
Researchers at NYU School of Medicine have, for the first time, identified a single gene that simultaneously controls inflammation, accelerated aging and cancer.
Now, a new study published on the medRxiv* preprint server proposes a rapid method to identify the mutations in B.1.1.7 (N501Y mutation and H69/V70 deletion) and the impact of this variant on various biomarkers in hospitalized patients. This is the first study that correlates the biomarker levels to SARS-CoV-2 variants.
Strategic Rare Earth Metals CEO, Tony Dibiase, announces today that the company has confirmed over 400,000 recipients for its proprietary, trademarked report covering Medical Conference topics for Fall 2010.
› Verified 1 days ago